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KEY POINTS: 32 
Question: What are the neurocognitive mechanisms that underlie the putative therapeutic effects of 33 
cannabidiol in psychosis? 34 
Findings: We show that a single oral dose of cannabidiol modulated activation in the striatum, medial 35 
temporal cortex and midbrain in clinical high-risk (CHR) patients, such that in each of these regions, the level 36 
of activation following administration of cannabidiol to CHR patients was intermediate between that in healthy 37 
controls and in CHR patients under placebo. 38 
Meaning: These results suggest that cannabidiol may normalize dysfunction in these brain regions, 39 


























ABSTRACT:  61 
 62 
Importance: Cannabidiol (CBD) has antipsychotic effects in humans, but how these are mediated in the brain 63 
remains unclear. 64 
Objective: To investigate the neurocognitive mechanisms that underlie the therapeutic effects of CBD in 65 
psychosis. 66 
Design: Parallel-group, double-blind, randomized, placebo-controlled design in people at clinical high risk 67 
(CHR) for psychosis. Healthy control (HC) participants were studied under identical conditions without any 68 
drug treatment. 69 
Setting: Academic Health Science Centre, UK 70 
Participants: Thirty-three medication-naïve CHR and 19 HC participants. 71 
Intervention: CHRs received a single oral dose of either 600mg of CBD (CHR-CBD) or a placebo (CHR-72 
PLB). HCs were not given any drug. All participants were then studied using functional magnetic resonance 73 
imaging (fMRI) whilst performing a verbal learning task.  74 
Main Outcomes and Measures: Brain activation during verbal encoding and recall, indexed using the blood-75 
oxygen level-dependent haemodynamic response (BOLD) fMRI signal. 76 
Results: Seventeen CHR-PLB [mean (SD) age= 25.35 (5.24) years; 10 females] and 16 CHR-CBD 77 
[mean (SD) age= 22.43 (4.95) years; 6 females] were compared with 19 HC [mean (SD) age= 23.89 (4.14) 78 
years; 8 females] participants. Brain activation (indexed using median sum of squares ratio of the BOLD 79 
effects model component to residual sum of squares) was analyzed from 16 CHR-PLB, 15 CHR-CBD and 19 80 
HC. CHR-PLB had reduced activation relative to HC in the right caudate during encoding (CHR-PLB: 81 
median=-0.027, IQR= -0.041, -0.016; HC: median=0.020, IQR= -0.022, 0.056; p<0.001), and in the 82 
parahippocampal gyrus and midbrain during recall (CHR-PLB: median=0.002, IQR= -0.016, 0.010; HC: 83 
median=0.035, IQR= 0.015, 0.039; p=0.000096). Within these three regions, activation in the CHR-CBD was 84 
greater than in CHR-PLB, but lower than in HCs (parahippocampal gyrus/ midbrain- CHR-PLB: median=-85 
0.007, IQR= -0.019, 0.008; CHR-CBD: median= -0.013, IQR= -0.027, 0.002; HC: median=0.034, IQR= 0.005, 86 
0.059; p<0.005): the level of activation was thus intermediate to that in the other two groups. There were no 87 
significant group differences in task performance. 88 





Conclusions and relevance: CBD may partially normalize alterations in parahippocampal, striatal and 89 
midbrain function associated with the CHR state. As they are critical to the pathophysiology of psychosis, the 90 


































Epidemiological and clinical studies have implicated regular cannabis use as a risk factor for the development1 120 
of psychosis, and for poor clinical outcomes after its onset
2-4
. Psychosis is also associated with alterations in 121 
the endocannabinoid system (reviewed here5,6), independent of exposure to cannabis. The endocannabinoid 122 
system thus represents a potential therapeutic target for psychosis
7,8
.  Its main central receptor, the CB1 123 
cannabinoid receptor is ubiquitous in brain
9,10
 and modulates the function of neurotransmitters, thought to be 124 
critically perturbed in psychosis, including dopamine and glutamate
11
. The constituent of cannabis responsible 125 
for its acute psychotomimetic effects
12-14
 and its association with the development and relapse of psychosis is 126 
delta-9-tetrahydrocannabinol (THC)1-4,15,16. In contrast, Cannabidiol (CBD), one of the major non-psychoactive 127 
constituents of cannabis, has broadly opposite neural and behavioural effects
17-23
. In particular, we have shown 128 
that CBD has opposing effects to THC on activation in the striatum
17,18
 during verbal memory and salience 129 
processing, on amygdala responses
17
 during emotional processing, and on the functional connectivity
19
 of these 130 
regions. Furthermore, pre-treatment with CBD blocks the experimental induction of psychotic symptoms by 131 





). CBD was non-inferior to antipsychotic medication in a 4-week 133 
clinical trial in first-episode psychosis26, and improved psychotic symptoms when used as an adjunct to 134 
antipsychotic medicaton in a 6-week trial in patients with chronic psychosis27.  135 
 136 
Although there is good evidence that CBD can have beneficial effects on psychotic symptoms, how these 137 
effects are mediated in the brain remains unclear. The present study sought to address this issue by examining 138 
the effects of CBD in individuals at clinical high-risk for psychosis (CHR). CHR subjects typically experience 139 
clinically significant psychotic symptoms that are qualitatively similar to those seen in patients with frank 140 
psychosis28, and are associated with high levels of distress29. Contemporary preclinical models propose that 141 
psychosis involves a perturbation of activity in the medial temporal lobe (MTL) that drives subcortical 142 
dopamine dysfunction through projections to the striatum and midbrain
30
.  Moreover neuroimaging studies in 143 
CHR subjects indicate that the later onset of psychosis is linked to alterations in parahippocampal structure31 144 
and function
32-34
 and to elevated striatal and midbrain dopamine activity.   145 





In the present study, on the basis of previous studies, we expected that CHR subjects would display altered 146 
responses in the MTL, midbrain and striatum relative to HC. Our main hypothesis was that CBD would 147 





 also play a key role in supporting the encoding and updating of contextual 149 
information in memory. Therefore, we employed the verbal paired associate learning task (VPA), which 150 
engages these processes and brain regions
13,14
. Furthermore, transient psychotomimetic effects of THC have 151 




 function and CBD
17
 has been shown to oppose these 152 
striatal effects of THC during this task.  153 
 154 
METHODS 155 
Detailed methods are included as part of supplementary material (see eMethods and Figure S1A for 156 
CONSORT diagram). Thirty-three antipsychotic medication-naïve CHR participants
28
 were recruited from 157 
early intervention services in the UK. Nineteen age-matched (± 3 years) healthy controls (HC) were recruited 158 
by local advertisement. All participants provided written informed consent. Individuals with history of 159 
previous psychotic or manic episode, neurological disorder or current DSM-IV diagnosis of substance 160 
dependence, IQ less than 70 and contraindication to MRI or treatment with CBD were excluded. 161 
Psychopathology was measured using Comprehensive Assessment of At-Risk Mental States (CAARMS; 162 
positive and negative symptoms)28 and state-trait anxiety inventory- state subscale (STAI-S)44 at baseline 163 
before drug administration. Two CHR participants were excluded, one from each of the CBD-treatment and 164 
placebo-treatment arms, after failing to correctly perform the imaging task, resulting in n=15 participants in the 165 
CHR-CBD group and n=16 in the CHR-PLB group.  166 
 167 
Using a parallel-group, double-blind, placebo-controlled design, CHR participants were  168 
randomized to either CBD (CHR-CBD) or placebo (CHR-PLB) treatment and received a single oral dose of 169 
600mg of CBD (THC-Pharm), a dose previously effective in established psychosis26, or an identical placebo 170 
capsule respectively. Three hours after taking the CBD or placebo capsule, participants underwent functional 171 
magnetic resonance imaging (fMRI) whilst performing a VPA task that we have previously used in 172 
conjunction with fMRI and pharmacological challenge
13,14
, including CBD administration
17
 (see eMethods for 173 





justification of CBD dose and time of fMRI scanning, and Figure S1B for CBD plasma levels). HC 174 
participants were investigated under identical conditions, but did not receive any study drug. 175 
All participants were asked to have refrained from cannabis for 96 hours, alcohol for a minimum of 24 and 176 
nicotine for 6 hours before scanning and any other recreational drugs for two weeks before the study day. A 177 
urine sample prior to scanning was used to screen for use of illicit drugs.  178 
 179 
The VPA task (described in detail in eMethods) comprised 3 conditions (encoding, recall, and baseline), with 180 
stimuli presented visually in blocks and accuracy of responses recorded online. During encoding, participants 181 
were shown word-pairs and asked to say ‘yes’ or ‘no’ aloud after each pair to indicate whether they went well 182 
together. The same word pairs were presented in the encoding condition 4 times, so that the associations could 183 
be learned over repeated blocks. During recall, one of the words from previously presented pairs was shown 184 
and participants were asked to say the word that it had previously been associated with. Subjects said “pass” if 185 
they could not recall the missing word. During baseline, participants viewed a pair of blank blue rectangles of 186 
identical dimensions as in the encoding/ recall condition.  187 
 188 
For each participant, the blood oxygen level–dependent haemodynamic (BOLD) response of the brain during 189 
each encoding and recall block, measured using a 3T MRI scanner (gradient echo sequence axially; 39 x 3mm 190 
slices, 3.3mm slice gap; 30ms echo time; compressed acquisition with a 2s repetition time and 3s silence), was 191 
contrasted with that during the baseline condition. 192 
 193 
Analysis | fMRI data were analyzed with software developed at the Institute of Psychiatry, Psychology and 194 
Neuroscience (XBAM, version 4.1), using a nonparametric approach to minimize assumptions  195 
(https://www.kcl.ac.uk/ioppn/depts/neuroimaging/research/imaginganalysis/Software/XBAM.aspx)45,46.  196 
Images were corrected for motion
47
, spatially smoothed and the experimental design was convolved with two 197 
gamma-variate functions to model the BOLD response. Using the constrained BOLD effects model, a best fit 198 
between the weighted sum of these convolutions and the change over time at each voxel was computed48. 199 
Following least-squares fitting of this model to the time series at each voxel, a sum of squares (SSQ) ratio 200 
statistic (ratio of the model component to residual sum of squares) was estimated for the encoding and recall 201 





conditions relative to baseline. Significance of the estimated SSQ values at each voxel was determined by 202 
permutation tesing49,50. SSQ ratio maps for each individual were transformed into standard stereotactic 203 
space51,45 and group activation maps were computed for each group in each drug condition by determining the 204 
median SSQ ratio at each voxel (over all individuals) in the observed and permuted data maps. Group 205 
activation maps for each condition were compared against each other (CHR-PLB vs HC and CHR-CBD vs 206 
CHR-PLB) using non-parametric repeated-measure analysis of variance (ANOVA)
45
. The voxel-wise 207 
statistical threshold was set at p=0.05 and the cluster-wise thresholds were adjusted to ensure that the number 208 
of false positive clusters per brain would be <1 (regions that survived this critical statistical threshold and the 209 
corresponding p values are reported).  210 
The BOLD response in each subject was modelled using only trials associated with correct responses in the 211 
recall condition. To test the hypothesis that activation in the CHR-CBD group would be intermediate between 212 
that of HC and CHR-PLB subjects we examined whether a linear relationship in brain activation (CHR-PLB > 213 
CHR-CBD > HC or CHR-PLB < CHR-CBD < HC) existed within the whole brain.  214 
 215 
Recall performance was analysed using repeated-measures analysis of variance. Correlational analysis between 216 
recall score and brain activation was conducted using Pearson’s test (two-tailed).  217 
 218 
RESULTS 219 
There were no significant group differences between the CHR-PLB and HC and CHR-PLB and CHR-CBD 220 
groups in demographic and clinical variables, except that the CHR-PLB group had fewer years of education 221 
than the HC group (Table 1).  222 
 223 
fMRI results 224 
Main effects of encoding and recall in healthy controls  225 
 226 
In HC, relative to the baseline condition, the encoding condition was associated with activation in the left 227 
anterior cingulate cortex, the right caudate, the left precentral gyrus, and the cuneus (eTable 1). The recall 228 
condition relative to the baseline condition was associated with activation in the left parahippocampal and left 229 





transverse temporal gyri, and decreased activation in the left middle occipital, the right lingual and inferior 230 
frontal gyri (eTable 2). 231 
 232 
 233 
Differences in activation associated with the CHR state (CHR-PLB vs HC) 234 
 235 
Encoding | During the encoding condition, CHR-PLB participants showed greater activation than HC in the 236 
right middle frontal gyrus and adjacent parts of the inferior frontal gyrus and insula; the left insula/ claustrum 237 
and adjacent inferior frontal gyrus and putamen; the right precentral gyrus and adjacent postcentral gryus and 238 
inferior parietal lobule; and the left cerebellum and adjacent lingual gyrus (Table 1, Figure 1A). Relative to 239 
CHR-PLB, HC showed greater activation in the right subcallosal gyrus/ caudate head; the left anterior 240 
cingulate; the right caudate tail extending to the posterior cingulate cortex; and in the right precuneus and 241 
cuneus (Table 2A, Figure 1A). 242 
 243 
Recall | During the recall condition, the CHR-PLB participants showed greater activation than HC in clusters 244 
encompassing the right inferior frontal, middle frontal and precentral gyri, and insula; the right cuneus, 245 
fusiform, lingual gyri and posterior cingulate gyri; and the left cerebellum and middle occipital and fusiform 246 
gyri (Table 2B, Figure 1B). HC showed greater activation in four clusters in the left hemisphere: these 247 
involved the parahippocampal gyrus, midbrain, cerebellum and thalamus; superior temporal and middle 248 
temporal gyri; superior and transverse temporal gyri; and middle frontal gyrus (Table 2B, Figure 1B). 249 
 250 
Effect of CBD on activation in CHR participants (CHR-PLB vs CHR-CBD) 251 
 252 
Encoding | During the encoding condition, the CHR-PLB group showed greater activation than the CHR-CBD 253 
group in a cluster in the left parahippocampal gyrus that extended into the superior temporal gyrus and 254 
cerebellum, but less activation in the precentral gyri (Table3A, Figure 1C). 255 
Recall | During the recall condition, the CHR-PLB showed less activation than the CHR-CBD group in three 256 
clusters, with foci in the left cingulate gyrus and adjacent body of caudate; the right precentral gyrus, extending 257 





to the cingulate gyrus; and in the medial frontal gyrus (Table 3A, Figure 1D). There were no clusters of greater 258 




Between-group linear analysis 263 
 264 
This analysis identified clusters where there was a linear pattern of activation across the 3 groups, such that 265 
activation in the CHR-CBD group was intermediate to that in the CHR-PLB and HC groups.  266 
 267 
Encoding | There were 7 clusters where encoding-related engagement was greatest in the CHR-PLB group, 268 
lowest in the HC group, and at an intermediate level in the CHR-CBD group. These involved the right inferior 269 
frontal and middle frontal gyri and insula; left insula and putamen; 3 clusters in the precentral gyri; right 270 
fusiform gyrus and adjacent cerebellum; left cerebellum and fusiform gyrus (Table 3B, Figure 2A-B; Also see 271 
supplementary figure S2A displaying all regions). The right inferior frontal gyrus, left insula and precentral 272 
clusters overlapped with the regions where the CHR-PLB showed increased activation during encoding 273 
relative to the HC group in the earlier paired comparison.  274 
 275 
There were 4 clusters where there was a linear between-group relationship in the opposite direction (CHR-276 
PLB< CHR-CBD<HC). These involved the left caudate head and putamen and anterior cingulate cortex; right 277 
subcallosal gyrus and caudate head; tail of the right caudate and adjacent posterior cingulate cortex; and the 278 
precuneus and right cuneus. In these clusters, activation during encoding was greatest in the HC group, lowest 279 
in the CHR-PLB group, and at an intermediate level in the CHR-CBD group (Table 3B, Figure 2A-B; Also see 280 
supplementary figure S1A displaying all regions). All 4 clusters overlapped with clusters where HC had shown 281 
greater activation than the CHR-PLB group during encoding in the previous paired comparison. 282 
 283 
Recall | In 3 clusters, recall-related engagement was greatest in the CHR-PLB participants, and lowest in HC, 284 
and at an intermediate level in the CHR-CBD participants. These clusters comprised the right inferior frontal 285 
gyrus extending to ipsilateral middle frontal gyrus and insula; precuneus extending to cuneus, lingual, middle 286 





occipital and fusiform gyri and cerebellum on the right side; and cerebellum extending to fusiform, lingual and 287 
inferior occipital gyri on the left side (Table 3C, Figure 2C-D; Also see supplementary figure S2B displaying 288 
all regions). All 3 clusters overlapped with clusters where the CHR-PLB had shown greater activation than HC 289 
during recall in the paired comparison.  290 
 291 
Conversely, there were 4 clusters where activitation was greatest in the HC group, lowest in the CHR-PLB 292 
group and at an intermediate level in the CHR-CBD participants. These included the left parahippocampal 293 
gyrus, midbrain and cerebellum; left thalamus; the left transverse temporal gyrus extending to superior 294 
temporal gyrus; and the left precentral and cingulate gyri and caudate body (Table 3C, Figure 2C-D; Also see 295 
supplementary figure S2B displaying all regions). The left parahippocampal gyrus and transverse temporal 296 
gyrus clusters overlapped with clusters where HC had shown greater activation than CHR-PLB participants 297 
during recall in the paired group comparison. 298 
 299 
Relationship between recall performance and brain activation: 300 
Across all participants, total recall score was directly correlated (r=0.28, p=0.046) with the level of left 301 
parahippocampal activation during recall. See eResults for exploratory analyses examining relationship 302 
between brain activation and symptoms.  303 
 304 
DISCUSSION 305 
As expected and in line with data from previous neuroimaging comparisons of CHR subjects and 306 
controls52-54, we found that under placebo conditions, CHR participants showed differential 307 
activation relative to controls in several regions. These regions of differential response included the 308 
three areas thought to be critical to the pathophysiology of the CHR state, the striatum (during 309 
verbal encoding), and the MTL and midbrain (during verbal recall). 310 
 311 
To test our main hypothesis, we identified regions where there was a linear pattern of activation 312 
across the three subject groups, such that the level of activation in CHR subjects given CBD was 313 
intermediate to that in the CHR-placebo and control groups. We found that this pattern of 314 
differential activation was evident in the striatum during encoding, and in the parahippocampal 315 





cortex and midbrain during recall. Moreover, these regions of differential activation overlapped with 316 
the areas where CHR participants under placebo conditions had shown altered activation in the 317 
paired comparison with the controls. These findings suggest that during verbal encoding, the 318 
administration of a single dose of CBD attenuated the reduction in the striatal response that evident 319 
in CHR participants relative to controls under placebo conditions. Similarly, administration of CBD 320 
appeared to attenuate the reduction in the parahippocampal and midbrain responses during verbal 321 
recall that was seen in CHR participants under placebo conditions relative to controls. Although this 322 
interpretation is cautious because the findings are based on cross-sectional as opposed to within-323 
subject comparisons, these data suggest that in these regions, CBD may partially normalise 324 
responses to verbal encoding and recall in CHR subjects. As there were no significant differences in 325 
memory performance, this differential activation was not attributable to differential task 326 
performance.  327 
 328 
Acute effects of CBD on responses in these areas in CHR participants are consistent with previous 329 
data from two studies that used a single dose of CBD in healthy volunteers. These studies indicated 330 
that in controls, CBD augmented parahippocampal and striatal activation
17,18
 during the same 331 
learning task17 as used in the present study and had a similar effect on parahippocampal and striatal 332 
responses during an attentional salience task18. In both of these studies, the administration of a single 333 
dose of THC induced transient psychotic symptoms, and the effect of THC on parahippocampal and 334 
striatal activation was the opposite to that of CBD.  335 
 336 
Preclinical models suggest that overactivity in the MTL region drives subcortical dopamine 337 
dysfunction through projections to the striatum and midbrain55,56. Moreover, neuroimaging studies in 338 
CHR subjects indicate that the subsequent onset of psychosis is linked to alterations in MTL 339 
structure31 and function32,34, and to elevated striatal and midbrain dopamine function57-59. Effects of 340 
CBD on parahippocampal, striatal and midbrain function in CHR participants are thus of particular 341 
interest as these areas may play a critical role in the pathophysiology of psychosis30. A partial 342 
normalization of dysfunction in these regions could contribute to the therapeutic effects of CBD that 343 
have been reported in patients with psychosis26,27 and anxiety disorders25. 344 






The molecular mechanism of action that may underlie the effects of CBD in CHR patients is 346 
unclear. CBD has effects on a number of signaling pathways11,60,61, including on the CB1 receptors 347 
62,63
 and may modulate glutamatergic neurotransmission particularly in the hippocampus through 348 
multiple pathways64-66 and striatal glutamatergic and CB1 receptor expression67. In patients with 349 
psychosis, the effects of CBD on psychotic symptoms have been related to its influence on levels of 350 
the endogeneous cannabinoid anandamide
26
. Future studies therefore need to investigate the 351 
neurochemical and receptor level mechanisms that may underlie the antipsychotic effects of CBD.  352 
 353 
Across all participants, the level of activation in the left parahippocampal cortex during verbal recall 354 
was directly correlated with total recall score during the task, consistent with the key role of this 355 
region in relational memory binding and retrieval 
68,69
 and in supporting association-based recall
70
. 356 
Attenuated parahippocampal engagement in CHR-PLB is consistent with meta-analytic and 357 
independent evidence from studies in patients with established psychotic disorders such as 358 
schizophrenia71-73 and in studies in those at clinical34,74 and familial/ genetic73,75 risk of psychosis. 359 
Further discussion of the results is presented as supplementary material (see eDiscussion 1).  360 
 361 
Limitations 362 
Our results need to be considered in light of certain caveats including related to study design (see 363 
eDiscussion 2).  364 
 365 
Conclusions 366 
This study suggests that a single dose of CBD in an experimental setting may partially normalise 367 
dysfunction in the MTL, striatum and midbrain in subjects at CHR for psychosis. It would be useful 368 
to now investigate whether similar modulatory effects are evident in patients who have received a 369 
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Table 1. Sociodemographic and clinical measures at baseline 650 







Age (years), mean±SD 23.89±4.14 25.35±5.24 22.43±4.95 HC vs CHR-PLB: p= 0.36 
CHR-PLB vs CHR-CBD: p= 0.11 
Gender (m: f) 16:8 7:10 10:6 HC vs CHR-PLB: p= 0.50 
CHR-PLB vs CHR-CBD: p= 0.30 
Education (years), mean±SD 16.94±1.59 12.00±3.69 14.50±3.06 HC vs CHR-PLB: p= 0.01 
CHR-PLB vs CHR-CBD: p= 0.15 
CAARMS positive symptoms - 42.94±29.46 40.19±20.79 p= 0.75 
CAARMS negative symptoms - 28.41±20.49 23.25±16.49 p= 0.43 
STAI-S - 38.94±10.17 40.31±9.06 p= 0.68 
Number of patients who made a transition to 
psychosis (n) 
- 1 1 p= 1 
Urine Drug screen (UDS) results: Clean - b 8 10 CHR-PLB vs CHR-CBD: p=0.45 
THC - 5 2 
Morphine - 0 1 
Benzodiazepines - 1 0 
PCP - 1 0 
Missing - 2 3 
Cannabis Use: Lifetime use (Current use) 
(n) 
- c 17 (7) 15 (7) Lifetime use: p=0.48; Current use: 
p=1 
Cannabis Use: Frequency- More than once a 
week 
- 12 11 p=0.38 
                      Once/ twice monthly  - 3 1 
                      Few times a year - 0 2 
                      Only once/ twice lifetime - 2 1 
Alcohol Use: Lifetime use  (Current use) (n) - d 13 (10) 12 (11) Lifetime use: p=1; Current use: 
p=0.59  
Alcohol Use: Frequency- Daily  - 2 1 p=0.59 
                      More than once a week - 4 4 
                      Few times a month - 3 4 
                      Few times a year - 2 3 
                      Only once/ twice lifetime - 2 0 
Nicotine Use: Lifetime use (Current use) (n) - e 7 (5) 11 (9) Lifetime use: p=0.16; Current use: 
p=1 
Nicotine Use: Frequency- Daily  - 6 8 p=0.68 
                       More than once a week - 1 2 
                       Few times a month - 0 1 
Total recall score 29.74±2.51 27.62±4.42 28.31±2.91 F2,48=1.84, p=0.17 
a- HC were selected to have minimal drug use and hence not compared with CHR groups on these parameters 651 
b- HC tested negative on UDS for all substances tested. 652 
c- Cannabis use < 10 times lifetime (no current users).  653 
d- Alcohol use: Lifetime users-13; Frequency (More than once a week- 5; Few times a month- 3; Few times a year- 654 
4) 655 
e- Nicotine use: Lifetime users-5 (2 current users); Frequency (Daily-2; Few times a month- 1; Few times a year- 1; 656 




















Table 2 A: Differences in activation between placebo-treated CHR (CHR-PLB, n=16) participants and healthy 672 
controls (HC, n=19) during verbal encoding 673 
CHR-PLB > HC 






X Y Z 
Middle frontal gyrus extending to inferior frontal 
gyrus and insula 
36 37 10 165 0.0001 
Claustrum/ Insula  
extending to inferior frontal gyrus and putamen 
-25 26 3 96 0.001 
Precentral gyrus extending to postcentral gyrus and 
inferior parietal lobule  
40 -7 36 134 0.00051 
Left cerebellum extending to lingual gyrus -40 -67 -16 77 0.0011 
CHR-PLB < HC 
Subcallosal gryus / caudate head  14 11 -10 72 0.00093 
Anterior cingulate -4 41 0 18 0.00093 
Caudate tail extending to posterior cingulate cortex 
18 -33 16 28 0.00021 
Precuneus extending to cuneus  
4 -63 30 156 0.00021 
TAL = Talairach coordinate system. *Corrected for less than 1 false positive cluster. 674 
675 





Table 2B: Differences in activation between placebo-treated CHR (CHR-PLB, n=16) participants and healthy 676 
controls (HC, n=19) during verbal recall 677 
CHR-PLB > HC 





X Y Z 
Inferior frontal gyrus extending to middle frontal gyrus, 
insula and precentral gyrus 
47 11 23 146 0.0001 
Cuneus extending to fusiform gyrus, lingual gyrus and 
posterior cingulate cortex  
29 -74 7 196 0.0001 
Cerebellum extending to middle occipital gyrus and 
fusiform gyrus  
-36 -63 -13 83 0.0015 
CHR-PLB < HC 
Parahippocampal gyrus extending to midbrain, cerebellum 
and thalamus 
-18 -26 -13 131 0.000096 
Superior temporal gyrus extending to the middle temporal 
gyrus 
-50 -18 0 80 0.00038 
Superior temporal gyrus extending to the transverse 
temporal gyrus  
-50 -30 13 33 0.003 
Middle frontal gyrus -25 11 33 57 0.0034 
























Table 3A: Differences in activation between placebo-treated CHR (CHR-PLB, n=16) and CBD-treated CHR 697 
(CHR-CBD, n=15) subjects during verbal encoding and recall 698 






X Y Z 
Encoding: CHR-PLB > CHR-CBD      
Parahippocampal gyrus, extending to superior temporal 
gyrus and cerebellum 
-29 -30 -13 75 0.0032 
Encoding: PLB-CHR < CBD-CHR 
Precentral gyrus 43 -7 30 40 0.0033 
-40 -11 36 72 0.0005 
Recall: PLB-CHR < CBD-CHR 
Cingulate gyrus, extending to body of caudate  -14 15 30 365 0.00010 
Precentral gyrus, extending to cingulate gyrus 43 -18 33 362 0.00010 
Medial frontal gyrus -7 0 49 61 0.0021 
TAL = Talairach coordinate system. *Corrected for less than 1 false positive cluster. 699 
There were no significant clusters for PLB-CHR > CBD-CHR during recall. 700 
  701 






Table 3B: Linear relationship in activation across all groups during verbal encoding (CHR-PLB, n=16; CHR-703 
CBD, n=15; HC, n=19) 704 





X Y Z 
CHR-PLB > CHR-CBD > HC      
Inferior frontal gyrus, extending to middle 
frontal gyrus and insula 
40 37 10 135 0.0001 
Insula, extending to putamen -36 11 10 112 0.0004 
Precentral gyrus -40 -11 30 39 0.0040 
-51 -4 16 34 0.0031 
40 -11 36 124 0.0002 
Fusiform gyrus, extending to cerebellum 43 -44 -13 53 0.0027 
Cerebellum, extending to fusiform gyrus -22 -52 -16 100 0.0004 
CHR-PLB < CHR-CBD < HC 
Caudate head, extending to anterior cingulate 
and putamen 
-14 22 0 44 0.0041 
Subcallosal gyrus/ caudate head 14 11 -10 87 0.0011 
Caudate tail, extending to posterior cingulate 
cortex 
18 -37 13 65 0.0038 
Precuneus, extending to Cuneus 4 -63 30 185 0.0001 
TAL = Talairach coordinate system. *Corrected for less than 1 false positive cluster.  705 





Table 3C: Linear relationship in activation across all groups during verbal recall (CHR-PLB, n=16; CHR-706 
CBD, n=15; HC, n=19) 707 
 708 






X Y Z 
CHR-PLB > CHR-CBD > HC 
Inferior frontal gyrus, extending to middle frontal gyrus and 
insula 
47 11 23 120 0.0001 
Precuneus, extending to cuneus, lingual, middle occipital and 
fusiform gyri and cerebellum 
25 -74 7 176 0.0001 
Cerebellum, extending to fusiform, lingual and inferior 
occipital gyri 
-36 -63 -13 73 0.0019 
CHR-PLB < CHR-CBD < HC 
Parahippocampal gyrus, extending to midbrain and 
cerebellum 
-18 -26 -13 82 0.0008 
Thalamus -7 -26 -3 33 0.0032 
Transverse temporal gyrus, extending to superior temporal 
gyrus 
-50 -26 13 33 0.0037 
Precentral gyrus, extending to cingulate gyrus and              
body of caudate 
-36 18 36 60 0.0016 





  714 





Figure Legends: 715 
 716 
 717 
Figure 1. Altered brain activation in CHR (CHR-PLB vs HC)  718 
A. Clusters showing greater (red/yellow) or reduced (blue/ green) activation in CHR-PLB compared to HC 719 
during the encoding condition.  720 
B. Clusters showing greater (red/yellow) or reduced (blue/ green) activation in CHR-PLB compared to HC 721 
during the recall condition.  722 
C. Clusters showing greater (red/yellow) or reduced (blue/ green) activation in CHR-PLB compared to CHR-723 
CBD during verbal encoding.   724 
D. Clusters showing greater (red/yellow) activation in CHR-PLB compared to CHR-CBD during the recall 725 
condition.  726 
The right side of the brain is shown on the right of the images. 727 
 728 
Figure 2. Effect of CBD on brain activation compared to placebo in CHR and healthy controls 729 
A. Clusters where activation during encoding differed across the 3 groups in a linear relationship. In the 730 
head of caudate (red/yellow), activation was greatest in HC, lowest in CHR-PLB and intermediate in 731 
CHR-CBD. The opposite pattern (CHR-PLB>CHR-CBD>HC) was seen in occipital regions (blue).  732 
B. Activation in each group in the right caudate head during encoding (arbitrary units; as indexed using 733 
median SSQ ratio)  734 
C. Clusters where there was a linear group difference in activation during recall. In the parahippocampal 735 
region and midbrain (red/yellow), activation was greatest in HC, lowest in CHR-PLB and intermediate 736 
in CHR-CBD. The opposite pattern (CHR-PLB>CHR-CBD>HC) was seen in occipital regions (blue).  737 
D. Median activation in each group in the midbrain during recall (arbitrary units; as indexed using median 738 
SSQ ratio)  739 
SSQ ratio statistic refers to the ratio of sum of squares (SSQ) of deviations from the mean image intensity due 740 
to the model (over the whole time series), to the SSQ of deviations due to the residuals. The right side of the 741 
brain is shown on the right of the images. 742 
 743 
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